Contact Us
-
Diet Specialists
Categories
-
Recent Posts
- How Anant Ambani struggled from weight gain due to steroids from asthma treatment – The Times of India
- Usha Chilukuri says hubby Vance adapted her vegetarian diet and learned how to cook Indian food for his mom-in law – The Tribune India
- Instead of crisps, kids could eat snacks from the sea: the forager chef looking to revolutionise Chiles diet – The Guardian
- Banana to mushroom: How a plant-based diet can help you hair and overall well-being – The Times of India
- Is it possible to lose weight in just a few weeks through water fasting? All about the viral weight loss – The Times of India
Archives
Search Weight Loss Topics: |
Category Archives: Testosterone
Contrasting of HEXO Corp. (HEXO) and Lipocine Inc. (NASDAQ:LPCN) – MS Wkly
Posted: November 2, 2019 at 6:44 am
This is therefore a contrasting of the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation in HEXO Corp. (NYSE:HEXO) and Lipocine Inc. (NASDAQ:LPCN). The two are both Drugs Generic companies that compete with one another.
Valuation and Earnings
Demonstrates HEXO Corp. and Lipocine Inc. earnings per share (EPS), top-line revenue and valuation.
Profitability
Table 2 shows us HEXO Corp. and Lipocine Inc.s return on equity, return on assets and net margins.
Analyst Ratings
The Ratings and Recommendations for HEXO Corp. and Lipocine Inc. are featured in the next table.
HEXO Corp.s average price target is $4, while its potential upside is 82.65%.
Insider & Institutional Ownership
Roughly 9.15% of HEXO Corp. shares are owned by institutional investors while 13.4% of Lipocine Inc. are owned by institutional investors. Insiders owned 8.04% of HEXO Corp. shares. Insiders Competitively, owned 3.4% of Lipocine Inc. shares.
Performance
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
For the past year HEXO Corp. has weaker performance than Lipocine Inc.
Summary
HEXO Corp. beats on 8 of the 10 factors Lipocine Inc.
Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of mens and womens health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing that has completed Phase 3 testing. The companys pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase 2 testing; and LPCN 1107, which has completed Phase 2 testing for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
Read the rest here:
Contrasting of HEXO Corp. (HEXO) and Lipocine Inc. (NASDAQ:LPCN) - MS Wkly
Posted in Testosterone
Comments Off on Contrasting of HEXO Corp. (HEXO) and Lipocine Inc. (NASDAQ:LPCN) – MS Wkly
Go or no go? Agile and Lipocine hope to make it third time lucky – Vantage
Posted: November 1, 2019 at 12:44 am
After some huge US approvals in recent months, November is shaping up to be quieter. There are no decisions on future blockbusters set for next month, Vantages regular PDUFA analysis shows.
However, some of the upcoming verdicts will still be a big deal for the companies involved. This includes Agile Therapeutics and Lipocine, which hope to bounce back from complete response letters for the Twirla contraceptive patch and the testosterone replacement therapy Tlando respectively.
Twirla's chances of getting approved got a boost yesterday, with an FDA advisory committee voting 14-1 that the benefits of the projects outweigh its risks an unexpected outcome given scathing briefing documentsreleased on Monday. The agency questioned the patch's efficacy, thoughAgile put unimpressive results from the pivotal Secure trial down to a high number of obese participants, in whom contraceptives do not work as well.
The FDA questioned Twirla's efficacy even in non-obese women, however, and also raised doubts about whether the project is a low-dose, and therefore potentially safercontraceptive, as Agile has claimed. Shares in the company recovered today after slumping on the briefing docs, but investors' wild ride might not be over yet.
Meanwhile, Lipocine will hope that an ambulatory blood pressure study will answer questions raised in the FDAs May 2018 CRL. The company believes that Tlando, an oral therapy, will have an edge over injectable testosterone products. Another oral contender got the FDA nod earlier this year, Clarus Therapeutics Jatenzo, andLipocine is embroiled in a legal wrangle with Clarus over intellectual property.
A project that should get a smoother ride is Shionogis S-649266, or cefiderocol, a novel antibiotic targeting Gram-negative pathogens. The project recently got an adcom thumbs up, with panellists voting14-2 in favour ofapproval for patients with complicated urinary tract infections and limited or no alternative treatment options.
The project has also shown promise in pneumonia. Still, as with many antibiotics, especially those saved for drug-resistant infections, succeeding commercially will be trickier.
Meanwhile, Redhill Biopharmas Talicia, which combines two antibiotics and a proton pump inhibitor, is awaiting a verdict in Helicobacter pylori infection. It has a good shot after a positive result in the Eradicate Hp2 trial, and a recent tie-up with Cosmo Pharmaceuticals should also give Redhill sufficient funds for launch.
However, sales expectations are not huge, with EvaluatePharma consensus predicting $27m in 2024.
Supplements
As for potential supplementary approvals, Lilly and Boehringer hope to get cardiovascular data on the label of their DPPIV inhibitor Tradjenta. However, the product has only shown noninferiority to placebo in the Carmelina study; with other diabetes drugs like the SGLT2s and GLP1s showing cardioprotective effects, the DPPIV class has been put in the shade.
Other decisions, including a verdict on Pfizers Humira biosimilar, continue to be expected sometime in the fourth quarter.
The biggest regulatory event of November is not an approval but rather an advisory committee meeting, for Amarins Vascepa. On November 14 panellists will consider the products expanded use for the reduction of cardiovascular events in patients with high triglycerides; the FDA had previously been expected to make a call here in September.
EvaluatePharma consensus forecasts 2024 Vascepa sales of $2.2bn, but Leerink analysts believe that, if the drug does get expanded approval, US revenues could exceed $4bn.
The rest is here:
Go or no go? Agile and Lipocine hope to make it third time lucky - Vantage
Posted in Testosterone
Comments Off on Go or no go? Agile and Lipocine hope to make it third time lucky – Vantage
Testosterone Replacement Therapy Market Competition, Status and Forecast, Market Size by Players, Regions, Type, Application by 2019-2025 – PR News…
Posted: October 30, 2019 at 8:46 pm
The Testosterone Replacement Therapy market research report gives a unique, first-time present and focused analysis of the size, patterns, division and lookout in the production and supply of Testosterone Replacement Therapy on the world. It also talks almost the market size of different sections and their progress features along with growth trends, various stakeholders like investors, traders, suppliers, CEOs, Research & Media, Global Director, Manager, President, SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the business and others.
In this report, we provide assessment of market definition along with the identification of key players and an analysis of their Production, Revenue, Price, Cost and Gross Margin their SWOT analysis for this market during the forecast period. Quantitative analysis of the industry from 2014 to 2025 by Region, Type, Application. Consumption assessment by regions. Industrial chain,upstream and downstream situation involved in this market.
Request Sample Copy of Market Research Report @ https://aimarketresearch.com/request-for-sample-report/41626
Geographically, global Testosterone Replacement Therapy market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players includingAbbVieEndo InternationalEli lillyPfizerActavis (Allergan)BayerNovartisTevaMylanUpsher-SmithFerring PharmaceuticalsKyowa KirinAcerus Pharmaceuticals
On the basis of product, we research the production, revenue, price, market share and growth rate, primarily split intoGelsInjectionsPatchesOtherFor the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Testosterone Replacement Therapy for each application, includingHospitalsClinicsOthersProduction, consumption, revenue, market share and growth rate are the key targets for Testosterone Replacement Therapy from 2013 to 2024 (forecast) in these regionsChinaUSAEuropeJapanKoreaIndiaSoutheast AsiaSouth America
If you have any special requirements, please let us know and we will offer you the report as you want.
Any query or need customization on the above report? Ask to our Industry Expert @ https://aimarketresearch.com/request-for-customization/41626
Key Points sheathed in the Testosterone Replacement Therapy Market Report Coverage:
Posted in Testosterone
Comments Off on Testosterone Replacement Therapy Market Competition, Status and Forecast, Market Size by Players, Regions, Type, Application by 2019-2025 – PR News…
What is menopause and perimenopause? – Sydney Morning Herald
Posted: October 27, 2019 at 9:46 am
Normal text sizeLarger text sizeVery large text size
You have to surrender to it, British comedian Dawn French proclaimed last year of menopause. "I promise that, afterwards, theres life."
Disturbed sleep. Thinning hair. Anxiety. Mood swings. Memory loss. Weight gain. Or, for some women, nothing much at all.
Despite being a fundamental biological transition affecting half the world's population, the symptoms of menopause have been deemed, traditionally, "secret" women's business. Now it's starting to become more a part of the conversation.
In Britain, women are gathering at pop-up "menopause cafes" to swap notes on their experiences. Workplace policies to cater for menopausal employees are up for discussion too: Britain's Labour Party wants to mandate them for large organisations, and a major media company introduced one in October.
What is menopause and what is it with a "peri" in front? What happens to women experiencing it? What happens afterwards? And is there a male equivalent?
On average, a woman in Australia will have 400 to 500 periods in her lifetime. Menopause is when the periods stop. The word itself stems from the Greek pausis ("pause") and men ("month"), meaning the "end of monthly cycles".
Women are on a path to menopause from birth. A baby girl has more than a million eggs in her ovaries. Steadily, as she ages, they deplete. By the time puberty hits, only about 300,000 remain, and so it goes, through her adult life.
[Menopause] represents the end of a womans reproductive life, says Martha Hickey, professor of obstetrics and gynaecology at the University of Melbourne. Specifically, menopause is the final menstrual period a woman experiences it is a one-off event. All women will go through menopause. It is inevitable."
(In a reproductive life spanning decades, the average Australian woman will have two or fewer babies.)
Menopause is considered a normal part of ageing when it happens after the age of 40. But some women can go through menopause early, either as a result of surgery such as hysterectomy, or damage to the ovaries such as from chemotherapy. When menopause happens before 40, regardless of the cause, it is called premature menopause.
The average age of menopause is about 51 but it can happen sooner, with most women experiencing symptoms in the lead-up which brings us to perimenopause.
Comparing notes on perimenopause: there's a lot to talk about. Credit:Illustration: Dionne Gain
Technically speaking, the symptoms women experience in the lead-up to menopause are actually perimenopausal. Peri, a Greek word for "around" or "near" menopause refers to this transitional state.
Perimenopause is when a woman's ovaries begin to make less oestrogen and the body responds. It's a phase that lasts until menopause and, on average, begins when a woman is 47, although it can last from a year to a decade.
As the body makes less oestrogen, the pituitary gland produces higher levels of signalling hormones follicle-stimulating and luteinising hormones in an effort to keep the ovaries producing eggs and to make oestrogen and progesterone levels "normal".
This can lead to ovulation occurring twice in a cycle, the second time during a period, which can lead to high hormone levels. In other cycles, ovulation might not occur at all.
Some women describe perimenopause as a time of hormonal chaos akin to a second-wave puberty. Symptoms also include hot flushes, changes in libido, mood swings, memory problems, vaginal dryness and a higher risk of osteoporosis. Periods can be less regular, lighter or heavier, last longer or be briefer.Womens' experiences vary greatly some barely register anything.
"It's what's called the menopause transition when those symptoms start," Professor Hickey says. "That can go on for a number of years and the end of that transitional period is a year after the final menstrual period."
Genetic factors play some role in timing. If your mother and other close female relatives had an early or late perimenopause, it's likely you will too. But various studies also point to lifestyle factors, such as smoking, being linked to early onset while other studies have pointed to alcohol consumption delaying perimenopause.
Credit:IStock
After a woman has had 12 consecutive months of amenorrhea (lack of menstruation) she is said to be postmenopausal.
Perimenopausal symptoms ease but health risks related to the loss of oestrogen rise. This includes a decrease in bone density, which can lead to osteoporosis, where bones become thin and fragile. It also includes weight gain, which can increase the risk of obesity, diabetes and cardiovascular disease. Women are advised to keep active, which also releases endorphins that improve mood, and to do strength training to increase blood flow and strengthen the heart.
Hormone replacement therapy (HRT), or menopausal hormone therapy (MHT) as it's now known, is currently the most effective type of treatment available for perimenopause symptoms; more than 300,000 Australian women and about 12 million women in Western countries are using it. But it has been linked with breast and ovarian cancers.
"All medications carry risk and benefits," Professor Hickey says. "A benefit of HRT is that it's really good for symptoms. A risk is that it does increase the risk of cancer. I don't think we should beat around the bush about that. But it varies by the type of hormone therapy you take and it might vary depending on how long you take it for."
The risks are greater, for example, for users of oestrogen-progestagen hormone therapy than for oestrogen-only therapy. A large study by the Institute of Cancer Research in London found that women who took hormone therapy for five years were 2.7 times more likely to develop breast cancer than those who did not. Recent research also suggests that, in some cases, the danger can persist for more than a decade after treatment stops.
Another study found that women using hormone therapy for between one and four years have a 60 per cent higher chance of developing breast cancer compared with those who have never used it.
The report's authors, who examined 58 studies across the world, found that of 108,647 women who developed breast cancer at an average age of 65, almost half had used hormone therapy.
When asked if women should avoid hormone therapy due to the increased risk of cancer, Professor Kelly-Anne Phillips, the founder of the Peter MacCallum Breast and Ovarian Cancer Risk Management Clinic, has said the decision should be made on a case-by-case basis.
"Some women will find, short-term, it can help relieve their symptoms," she saidearlier this year.
Professor Phillips warned, however, that women who had been on hormone therapy for a year should have their treatment reviewed, adding there were alternatives for treating symptoms including weight loss, moisturisers for vaginal dryness and avoiding caffeine or alcohol.
The 'grandmother theory" is one explanation for menopause in humans.
Apart from humans, most mammals stay fertile until the ends of their lives. There are a few exceptions: killer whales, short-finned pilot whales, belugas and narwhals can live for decades beyond their reproductive years. Guppies also appear to go through a fish version of menopause.
But long postmenopausal lifespans are an aspect of biology that appears to be at odds with natural selection. Why do women suddenly stop having periods when they still have at least a third of their lives to live, during which they could be producing offspring?
Some experts, including Professor Hickey, believe high death rates of mothers during childbirth throughout history emphasised the importance of grandmothers in rearing future generations, unhindered by more children of their own. This is known as the grandmother theory.
Not really but andropause can affect men older than 40. Andropause is the gradual reduction of the male sex hormone (testosterone) with increasing age. Its symptoms include sexual dysfunction, weakness, fatigue, insomnia, loss of motivation, mood disorders and reduction of bone density. Though the symptoms aren't as severe as those of menopause, they can last for as long as 15 to 20 years.
An egg surrounded by sperm.Credit:Alamy
Although eggs succumb to menopause, pregnancy is still possible using a donor egg. During perimenopause, ovulation can occur, meaning a woman can conceive naturally, even if she is using hormone therapy.
When UK based former magazine editor Lynnette Peck and her friend Paula Fry first began to experience symptoms of perimenopause they found they had no safe space to share their feelings on the matter. In a bid to open up dialogue, they started a secret Facebook page in 2017.
Word got around quickly. Soon they had more than 700 members and then Feeling Flush was born; a public online community for women across the world to connect.
"We wanted women, including ourselves, to have places to share information and educate each other and have a moan," Ms Peck says.
"Women mostly ask us about hormone replacement therapy and the pros and cons. We are not medical experts so we point them to people who are. There is now a conversation. It was hidden before. Here in the UK, even political parties and huge brands are getting involved."
Professor Hickey notes that women make up almost half of the workforce in Australia and two-thirds of the voluntary sector. They continue to look after children across generations and are often the primary carer for parents.
Our society has a big a focus on youth and the preservation of youth and menopause is a maker of age in women and ageing in women is not a topic we still have very much discussion about," Professor Hickey says.
"It's quite likely that women who experience menopause may not have been informed fully about what to expect. It's quite possible a lot of men don't know very much about menopause at all."
Last week, British free-to-air television Channel 4 launched a menopause policy to support women experiencing perimenopausal symptoms such as hot flushes, anxiety and fatigue by giving them access to flexible working arrangements and paid leave if they feel unwell.
It's a shift Professor Hickey wants in Australia. She would like to see menopause treated as a "diversity issue" with workplaces actively supporting women experiencing it.
"Pregnancy would be a similar example: only women get pregnant, and we've learnt to adapt, and I think we need to take a similar perspective to menopause."
Melissa Cunningham is The Age's health reporter.
More:
What is menopause and perimenopause? - Sydney Morning Herald
Posted in Testosterone
Comments Off on What is menopause and perimenopause? – Sydney Morning Herald
Global Testosterone Replacement Therapy Market – Expected To Be Driven By Increasing Industry Penetration -2025 – Feed Chip
Posted: October 25, 2019 at 11:42 pm
Feed Chip Science Global Testosterone Replacement Therapy Market Expected To Be Driven By Increasing Industry Penetration -2025
October 25, 2019 Innovate Insights
The given report is an excellent research study specially compiled to provide latest insights into critical aspects of the Global Global Testosterone Replacement Therapy Market Market by INNOVATE INSIGHTS.
The worldwide market for Global Testosterone Replacement Therapy Market is expected to grow at a CAGR of roughly over the next five years, will reach million US$ in 2024, from million US$ in 2019, according to latest industry study.
The Global Global Testosterone Replacement Therapy Market Market pursuers will discover this report exceptionally advantageous in comprehension the Market showcase in integrity. The angles and data of the report utilizing figures, structured presentations, pie graphs, and other visual portrayals. This escalates the Global Testosterone Replacement Therapy Market Market pictorial portrayal and furthermore helps in getting the Global Testosterone Replacement Therapy Market Market business actualities much better. The Global Testosterone Replacement Therapy Market Market advertise is probably going to develop at a noteworthy CAGR. The principle goal of report is to direct the client comprehend the Market advertise as far as its definition, order, potential, most recent patterns, and the difficulties that the Global Testosterone Replacement Therapy Market Market advertise is confronting.
Key players operating world wide: AbbVie, Pfizer, Eli Lilly, Teva Pharmaceuticals, Mylan, Bayer HealthCare Pharmaceuticals, Antares Pharma, Ferring Pharmaceuticals, Allergan, Antares Pharma, Sandoz, Clarus Therapeutics, Juniper Pharmaceuticals, Endo International, Acerus Pharmaceuticals, Forendo Pharma, MetP Pharma, Repros Therapeutics
Premium Sample report of Global Testosterone Replacement Therapy Market Market @ https://www.innovateinsights.com/report/global-testosterone-replacement-therapy-market-report-history-and/48838/#requestsample
Some key points of Global Testosterone Replacement Therapy Market Market research report:
Strategic Developments: The custom analysis gives the key strategic developments of the market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.
Market Features: The report comprises market features, capacity, capacity utilization rate, revenue, price, gross, production, production rate, consumption, import, export, supply, demand, cost, market share, CAGR, and gross margin. In addition, the report offers a comprehensive study of the market dynamics and their latest trends, along with market segments and sub-segments.
Analytical Tools: The Global Global Testosterone Replacement Therapy Market Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.
Request inquiry of Report Before Purchasing (Higher Preference For Corporate email ID User): https://www.innovateinsights.com/report/global-testosterone-replacement-therapy-market-report-history-and/48838/#buyinginquiry
Segmentation by Product Type: Gels, Injectables, Patches, OtherMarket Growth by Applications: Hospitals, Clinics, Other
Benefits of Purchasing Global Testosterone Replacement Therapy Market Market Report:
Inimitable Expertise: Analysts will provide deep insights into the reports.Analyst Support: Get your query resolved from our team before and after purchasing the report.Customers Satisfaction: Our team will assist with all your research needs and customize the report.Assured Quality: We focus on the quality and accuracy of the report.
Access complete overview report here: https://www.innovateinsights.com/report/global-testosterone-replacement-therapy-market-report-history-and/48838/
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Global Testosterone Replacement Therapy Market market, to estimate the size of various other dependent submarkets in the overall market.The detail information about In-Depth Analysis, Business opportunities, Market growth rate analysis Available in Full research report.
*If you have any special requirements, please let us know and we will offer you the report as you want.
** The Values marked with XX is confidential data. To know more about CAGR figures fill in your information so that our business development executive can get in touch with you.
Conclusively, This report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.
Thanks for reading this article, you can also get separate chapter wise or region wise report versions including North America, Europe or Asia.
For More Information Kindly Contact:Innovate Insights49 Lincoln Highway,Kearny, NJ 07032, USAUnited StatesEmail: [emailprotected]Tel: +1 518 620 4504
Posted in Testosterone
Comments Off on Global Testosterone Replacement Therapy Market – Expected To Be Driven By Increasing Industry Penetration -2025 – Feed Chip
Richardson Pain & Wellness Offering Testosterone Replacement Therapy, Male Hormone Replacement Therapy, Medically Assisted Weight Loss, and…
Posted: October 23, 2019 at 9:41 pm
You may want to sort out your chronic pain, look and feel younger, or maybe you would like to increase your energy level so you can pursue your goals.
Well, thankfully the team at Richardson Pain & Wellness is ready and able to help you do it, their doctors have many years of experience with custom-made wellness plans suited to each patients individual needs and wants, ensuring that they not only feel renewed in our office but for many years to come. All you have to do is set up an appointment with one of the doctors, and they will help you get started and create a plan to suit your needs and interests.
The pain clinic Richardson offers testosterone replacement therapy and hormone replacement therapy at Richardson. If tests show that you do have low T and you notice the condition taking over your life, then you should consider hormone replacement therapy in Richardson to supplement the bodys production of testosterone to levels of young adulthood.
Furthermore, replacement therapy may lead to desired results, such as greater muscle mass and a stronger sex drive.However, Richardson Pain & Wellness the testosterone therapy to treat low T is vital is surprised to make you aware. Due to the mental and physical risks may develop with self-administered artificial or synthetic testosterone.The testosterone therapy Richardson is suitable for those with low testosterone, call Richardson Pain & Wellness today to schedule a consultation.
Also, Richardson offers the residents of medical weight loss programs Richardson, which they designed with care and precision to suit each patient. So, what does the weight loss program entail? Well, they create a customized diet, exercise plan, and supplement program, they believe it is essential to focus on workingwith their body for weight loss, not against it.
Richardson Pain & Wellness creates a weight loss program that is put together by two doctors alongside a registered dietitian. These professionals have years of experience in the field of wellness and pain management. For instance, Janel Kobza-Chukhman has over 15 years of nutrition counseling experience. A considerable advantage of Richardson Pain & Wellness is that they provide you with all three elements; a diet plan, an exercise plan, and supplements. Whats even better is the result you achieve after all the hard work of keeping to your specified program.
Richardson believes the key to healthy weight loss is following a plan that is specially made for you, and they are proud of the weight-loss programs they provide for their clients.
Contact the Richardson pain clinic today if you would like to book an appointment and have one of their experienced doctors custom make a wellness plan to suit your needs or if you want to start your weight-loss journey today. Ring the clinic on (972) 907-1125, or you can email alignrightchiropractic@gmail.com to schedule an appointment.
See the original post:
Richardson Pain & Wellness Offering Testosterone Replacement Therapy, Male Hormone Replacement Therapy, Medically Assisted Weight Loss, and...
Posted in Testosterone
Comments Off on Richardson Pain & Wellness Offering Testosterone Replacement Therapy, Male Hormone Replacement Therapy, Medically Assisted Weight Loss, and…
The Good, the Bad and the Ugly of UFC on ESPN 6 – Sherdog.com
Posted: October 23, 2019 at 9:41 pm
Lauzon turned back time by defeating JonathanPearce. It was the perfect way to say goodbye to the sport forLauzon, who has sustained a great deal of damage over the course ofhis career and stepped into the cage riding a three-fight losingstreak. In front of his beloved Bostonians and with the samesignature violence that makes him a surefire Hall of [emailprotected]#$%&gAwesome candidate, Lauzon big-brothered the up and comer withground-and-pound from a half nelson. While Lauzon was hesitant tocommit to retirement immediately after the fight, UFC PresidentDana White seemed ready to encourage him to end his career on ahigh note. Lauzon turned what looked like a setup match for thenext generation -- Pearce was on a five-fight winning streak thatincluded an appearance on Dana Whites Contender Series and twoothers in Bellator MMA -- into the perfect swan song.
Rosa and Costa entered the arena hoping to the right ship, as bothmen had experienced defeats in their previous outings. In stylepairings that promised fireworks against MannyBermudez and the ironically named BostonSalmon, Rosa and Costa came out in the winning side of thosefireworks. With the exception of KyleBochniak, who was outclassed by an impressively poised SeanWoodson, the city managed to enjoy home-cooked victories. Whilethe UFC has rightfully received criticism for not booking mainevents in locations more appropriate for the fighters, it does agood job of keeping a local feel to the undercards. Results likethis help elevate an otherwise routine event.
Unfortunately for Weidman, the extra 20 pounds on the scale didnothing to resuscitate his career. Reyes heavy hands and technicalacumen proved too steep of a mountain to climb, as the formerchampion fell victim to a backstepping left hand and follow-uphammerfists on the ground. Less than two minutes into the contest,Weidmans light heavyweight campaign came to a screeching halt. Hadthings gone differently, it seemed almost certain that theSerra-Longo Fight Team standout would have been tapped to standopposite Jon Jones in abattle over the light heavyweight title. Say what you will aboutwho would have been favored to win that fight, but Weidman wouldhave added name value to the blue corner that is not readilyavailable at 205 pounds. Similar to when rumors swirled aboutRockhold being fast tracked if he passed his first test in a higherweight class, the potential involving Weidman went unfulfilled andthe dominant champion was left to look elsewhere for a marqueematchup.
A victory over Reyes would have provided a simple answer to thequestion of what was next for Weidman, along with a built-in chanceto redeem the misfortune that has plagued his career in recentyears. Now, another decisive loss puts that question in bold print.There just is not an easy answer for Weidman at this point. Hecould elect to remain at 205 pounds. However, his ceiling seemspretty obvious. The damage he sustained in wars at 185 pounds didnot just magically go away with a move up in weight. Just like wewitnessed with James Vick atUFC Fight Night 161, the leap in weight may have come too late.Should Weidman decide to run it back at middleweight, he will facethe same challenges associated with his inability to absorbpunishment. The top names in the division would be no kinder to hischin, including KelvinGastelum, who managed to hurt Weidman badly before beingsubmitted two years ago. Plus, Weidman would be back to draininghis large frame again.
It seems likely that Weidman and his team will examine what lifeoutside of competition looks like. After being knocked out fivetimes in six fights and nearly suffering the same fate in his lonevictory during that stretch, it looks like we are witnessing theend of a great career.
Hardy has made four appearances inside the Octagon so far. Half ofthose them have gotten bogged down with rule-bending controversy.From a competitive standpoint, those controversies have distractedfrom his clear growth as a fighter under the direction of AmericanTop Team. Now, his taking two puffs from a prescribed inhalerbetween the second and third rounds has taken the conversation awayfrom the things he did right in the cage in Boston.
By adding more elements to his game, Hardy managed to outpoint thestubborn Ben Sosoli.Leg kicks from the outside, effective defensive footwork and theability to do something other than quickly blast his opponent tobits were on display. However, when he used his medication betweenrounds, it called the entire fight into question. Going thedistance for the first time and handling a consistent pace withoutmuch issue would normally something to commend for a fighter whosecareer mainly consists of short circuiting the opposition in quickfashion. How can we rightfully look at Hardy lasting the full 15minutes as a positive if he needed his asthma medication to doso?
The fault does not exclusively rest with Hardy or trainer Din Thomas,who was the primary target of Whites criticism after the fact.Granted, when most athletic commissions only allow water or in somecases an electrolyte-enhanced beverage like Gatorade in the corner,there is no reason to believe that medication that enhancescardiorespiratory function is permissible during a fight. However,the Massachusetts State Athletic Commission did plainly tell Hardyand his team that it was permitted. The level of confusion betweenthe commission (which quickly overturned the decision to ano-contest), UFC Vice President of Regulatory Affairs Marc Ratner,the commentary booth, media and amateur online investigators wastruly bizarre to witness. Is Albuterol allowed between rounds? Whatabout the potential abuse of asthma medication in relation tosports performance? Is Massachusetts clear enough about what is andis not allowed in competition? Why was the fight allowed tocontinue into that pivotal third frame in the first place?
As the infamous 1983 boxing match between Luis Resto and BillyCollins Jr. showed, asthma medication can be used a PED to increasecardio capacity. As the testosterone replacement therapy era of MMAshowed, fighters can and will abuse the use of therapeuticexemptions to gain a competitive edge. It sounds like a recipe fordisaster if the commission does not address this properly.
Clear improvement and two dominant wins from Hardy have beensandwiched between two displays of poor judgment. Those trustedwith overseeing the action in a responsible fashion get a solidfailing grade on clearly communicating the proper rules andhandling discrepancies as they arise. Once again, Hardysperformance inside the cage was overshadowed by other factors.
See the original post here:
The Good, the Bad and the Ugly of UFC on ESPN 6 - Sherdog.com
Posted in Testosterone
Comments Off on The Good, the Bad and the Ugly of UFC on ESPN 6 – Sherdog.com
Testosterone Replacement Therapy Market to Expand at a Healthy 4.2% CAGR from 2016 to 2024 – Statsflash
Posted: October 23, 2019 at 9:41 pm
The global testosterone replacement therapy market rides on the back of technology. As consumer focus shifts from access to comfort, players in the market for testosterone replacement therapy are looking at new opportunities to capitalize on the potential. This exclusive report from Transparency Market Research will take you through an extensive analysis of every aspect in the testosterone replacement therapy market that is critical for defining your success strategy. It offers prudent information on markets under currents, trends that will open new doors, factors that will remain important, challenges that need to be overcome, prevailing competition in the market, and the geographical landscape.
Based on a tested and proven research methodology, our research analysts bring to you fact-checked information. Besides presenting the current market figures, our analysts provide you with accurate forecasts that can be the game-changer for your winning strategies for tomorrow. On the other hand, our reports also offer tailor-made insights. Further, our reports are packed with experts viewpoints which are transcribed from interviews conducted by our analysts.
For Right Perspective & Competitive Insights, Request For A Sample Here
For every market, information on leading players can be the difference between success and failure, be it a prominent brand or not. Our reports cover every significant players in the global testosterone replacement therapy market providing information about the company profile, products, winning strategies and market revenues. Not just that, TMR also provides information on the competitive landscape, helping you understand what impacted in one company being the market leader and others not. It also explains on the companies imperatives that define their success in the global market for testosterone replacement therapy.
Healthcare, unlike most industries, is typical of the region. Humans have multiple races and hence their genetic makeups are different. As a result, one condition has different impacts depending on the region. Therefore, information on how consumer requirements are different in regional landscape of the global testosterone replacement therapy is provided her in the report. Further, the economic capabilities of a country has a huge impact on healthcare infrastructure. TMRs report analysis the current economic scenario and also brings to you information on affordability during the coming years.
To Clarify Your Doubts About The Report, Request A Brochure Here
From market share to region-specific strategies, the report covers it all. At the same time, players in the testosterone replacement therapy market who are looking to expand might want to assess the potential of a prospective region. Our reports can provide you with custom-made insights for specific regions in the global testosterone replacement therapy market. The geographical analysis also covers regions-specific factors that could turn out to be hurdle for growth in the coming years.
Read the original here:
Testosterone Replacement Therapy Market to Expand at a Healthy 4.2% CAGR from 2016 to 2024 - Statsflash
Posted in Testosterone
Comments Off on Testosterone Replacement Therapy Market to Expand at a Healthy 4.2% CAGR from 2016 to 2024 – Statsflash
How to enjoy sex during the menopause – Yahoo Lifestyle
Posted: October 23, 2019 at 9:41 pm
The menopause brings everything from hot flushes and night sweats to insomnia and mood swings.
But its affect on a womans sex life is less commonly discussed.
Going through the change often triggers vaginal dryness, which can make intercourse agonising.
Hormonal changes combined with sleepless nights and embarrassment over the middle age spread also puts many off being intimate.
With today marking World Menopause Day, Yahoo UK asks experts how women can continue to enjoy sex while going through the change.
Menopause usually strikes between 45 and 55, however, one in 100 women experience symptoms at under 40, NHS statistics show.
Most endure symptoms for around four years, but one in 10 battle the discomfort for up to 12 years.
While many blush at the thought of vaginal dryness, menopause specialist nurse Kathy Abernethy warns it is almost an inevitability.
Vaginal dryness comes about when the cells in the vagina change, she told Yahoo UK. The vagina is like a sponge; it gives during intercourse. Menopause makes it become rigid.
Vaginal dryness puts many menopausal women off sex. [Photo: Getty]
The uncomfortable symptom affects a womans day-to-day life, with many enduring pain and itching when they walk or exercise. When it comes to sex, vaginal dryness can be agonising.
It feels like sandpaper, Ms Abernethy said. You get a friction feeling when the penis should just glide in.
READ MORE: 10 of the best menopause relief products
While uncomfortable for all, gynaecologist Dr Michael Savvas warns young menopausal women may particularly suffer.
Hormone levels drop off more steeply in menopausal women under 40, he told Yahoo UK. Its unnatural for a young woman to have low oestrogen or testosterone.
While it may sound bleak, menopausal women do not have to wave goodbye to their sex lives.
It's important to communicate with your partner that its an issue, Ms Abernethy said.
Lots of women are suffering in silence. Sex is not an open conversation but men dont get it until theyre told.
Being open with your other half may also stop them blaming themselves, with many men feeling shunned when their partner turns down their advances, Ms Abernethy said.
When it comes to enjoying sex again, ramping up foreplay will not solve the problem.
READ MORE: Moody? Tired? Forgetful? You may be peri-menopausal even in your 30s!
Ms Abernethy recommends women opt for vaginal lubricants, which can be bought on the high street.
Some may also benefit from the hormonal replacement therapy (HRT) vaginal oestrogen, which can come as a pessary, cream or vaginal ring. Unlike other forms of HRT, vaginal oestrogen has not been linked to cancer or blood clots.
Although both lubricants and vaginal HRT are effective, they do not cure vaginal dryness, with women relying on the treatments every time they have sex.
For the best results, it is important women seek help as soon as they experience discomfort.
Vaginal dryness doesnt get better on its own; treatment is required, Ms Abernethy said.
Eating a diet rich in plant-based oestrogen may also help. Speaking to Yahoo UK, Tania Adib - a consultant gynaceologist at The Medical Chambers Kensington - recommended chickpeas, nuts and seeds.
Limit your intake of alcohol as drinking over the safe recommended limit can lower oestrogen levels and lead to vaginal dryness as a result, she added.
While vaginal dryness stops some menopausal women being intimate, for others, a low sex drive means they simply do not want to.
Reduced libido affects lots of women, Ms Abernethy said.
Hormonal changes are often to blame, with testosterone, which gives a woman her sex drive, falling during the change.
It could also be caused by the ageing process, Ms Abernethy said. Women feel less sensual than they did when they were younger.
Menopause symptoms like insomnia also leave women exhausted and not in the mood. And relationships can get stale in middle age.
Hormonal changes and ageing also trigger abdominal weight gain, which often leaves women with low self esteem.
To get back in the mood, Ms Abernethy first recommends women make sex comfortable, via lubricants or other treatments.
Testosterone therapies can then help them feel more passionate. Testosterone is not licensed for use in women in the UK, however, doctors can give it off label.
READ MORE: The menopause timeline: What to expect from each stage
Doctors prescribe products licensed for men at a much reduced dose, Dr Savvas said.
When given appropriately, very few develop male characteristics, like facial hair, he added.
As well as getting women in the mood, testosterone may also help women enjoy intercourse.
Many report finding sex less pleasurable and finding it hard to orgasm, testosterone helps, Dr Savvas said.
Vaginal oestrogen aside, the medic also recommends often forms of HRT, like tablets, patches and implants.
The treatment has hit the headlines over the years after links to breast, ovarian and womb cancer.
According to Dr Savvas, however, HRT is extremely safe, particularly for those with no personal or family history of disease.
In early-onset menopause, HRT could even keep women healthy, he adds. Experiencing the change too soon can trigger osteoporosis and heart disease, with oestrogen being linked to both bone and cardiovascular health.
For some, their libido returns post-menopause, but Ms Abernethy stresses a womans attitude to ageing is important.
If youre hankering after a 20 year old's body, it's not going to happen, she said. You should accept your 50-year-old body is still hugely attractive to your partner.
To break down the stigma around sex during the menopause, Ms Abernethy urges people to discuss it more openly.
Menopause is a natural part of our lives, she said. It should be talked about.
Read the rest here:
How to enjoy sex during the menopause - Yahoo Lifestyle
Posted in Testosterone
Comments Off on How to enjoy sex during the menopause – Yahoo Lifestyle
Global Testosterone Replacement Therapy Market Industry: A Latest Research Report to Share Market Insights and Dynamics – Healthcare News
Posted: October 17, 2019 at 8:42 pm
Testosterone Replacement Therapy Market presents a detailed competitive outlook and systematic framework of testosterone replacement therapy market at a global uniform platform. The report commences with the market summary, chain structure, past and present market size in conjunction with business opportunities in coming back years, demand and lack, numerous operators and restrainers. The research study exhibits the historical data that analyzes respective analytical tools including porters five forces analysis, supply chain analysis, pricing analysis, and regulatory analysis. It offers a detailed analysis of top-line vendors along with revenue and cost-profit analysis.
Testosterone Replacement Therapy Market reports provide 10 years pre-historic and forecast for the sector and involve data on socio-economic data of global. Key stakeholders can analyze statistics, tables & figures mentioned in this report for strategic planning which lead to the success of the organization.Testosterone Replacement Therapy Market reports provide a comprehensive overview of the global market size and share. Global testosterone replacement therapy Market report provides strategists, marketers and senior management with the critical information they need to assess the global testosterone replacement therapy sector.
Get Sample For Technological Breakthroughs (Use Company eMail ID to Get Higher Priority) at: https://market.us/report/testosterone-replacement-therapy-market/request-sample/
Research study helps to examine the change in market dynamics, geographical market volume, technological innovations, and testosterone replacement therapy business opportunities in the coming years. The research covers a crucial market segmentation analysis that is a rich source of all essential segments including testosterone replacement therapy types, applications, technologies, end-users, and territories. It provides key essentials for equipment suppliers, education & research institutes, developing companies, research experts, service providers, operators, and investors. It enables industry players to target the demands and preferences of their consumers and achieves the market competitive advantage by targetting different customers and target specific products to meet their demands. The report presents up to and coming data beside fundamental insights associated with the market estimate over a time frame, from 2020 to 2029.
Global Testosterone Replacement Therapy Market Key Manufacturers:
AbbVieEndo InternationalEli lillyPfizerActavis (Allergan)BayerNovartisTevaMylanUpsher-SmithFerring PharmaceuticalsKyowa KirinAcerus Pharmaceuticals
Global Segmentation Analysis 2029:
Global Testosterone Replacement Therapy Market research supported Product sort includes:
GelsInjectionsPatches
Global Testosterone Replacement Therapy Market research supported Application Coverage :
HospitalsClinics
Leading Market Regions:
Center East and Africa Testosterone Replacement Therapy Market (Saudi Arabia, UAE, Egypt, Nigeria, South Africa)
North America Testosterone Replacement Therapy Market (United States, Canada, Mexico)
Asia Pacific Testosterone Replacement Therapy Market (China, Japan, Korea, India, Southeast Asia)
South America Testosterone Replacement Therapy Market (Brazil, Argentina, Colombia)
Europe Testosterone Replacement Therapy Market (Germany, UK, France, Russia, Italy)
Place An Inquiry Before Investment (Use Corporate Details Only):https://market.us/report/testosterone-replacement-therapy-market/#inquiry
Some Notable Report Offerings
1. Introduction of testosterone replacement therapy with progress and situation in the market.
2. The production technique of testosterone replacement therapy along with research and patterns observed.
3. Study of international testosterone replacement therapy market top producers, including Company Profile, Information about commodities, manufacturer data, and Contact Information.
4. Scrutiny of Global testosterone replacement therapy market potential, opportunities, costing of production, price, and revenue.
5. Survey of testosterone replacement therapy Market with Comparison, Deployment, Usage, and Import and Export.
6. testosterone replacement therapy market Survey with Market Condition from a competitive edge by means of Companies and Regions.
7. 2020-2029 Market Anticipation of International testosterone replacement therapy Market with Value, Earnings, Market Segments, Supply, Requirement, Import, and Export.
8. Current factors affecting the market sectors of APAC, Europe, North America, and South America.
9 .testosterone replacement therapy Market Analysis of Industry Chain Pattern, Primary Resources, manufacturing sector.
10. Consequently, the report probes the international crucial testosterone replacement therapy market leaders thoroughly.
View Details of Testosterone Replacement Therapy Market Research Report,click the link Here: https://market.us/report/testosterone-replacement-therapy-market/
About Us:Market.us offers its clients a one-stop solution platform for all market research needs. Our focus on custom research, consulting projects, syndicate reports covers a variety of industries, sectors, and verticals, and we cover niche market titles, and we also cater to client-specific requirements. Analysts at Market.us have access to large databases of statistical information, Customs Import and Export Database, Industry Association Database, etc., besides expert resources and participants. Our expert panel includes specialists in industries and sectors such as energy, automotive, chemicals, healthcare, medical, ICT consumer goods, banking & finance, mining & minerals, food and beverages, agriculture and other related fields, aerospace, machinery & equipment, etc., apart from professional survey teams and competent teams of data analysts and researchers.
Get in Touch with Us :
Mr. Benni Johnson
Market.us (Powered By Prudour Pvt. Ltd.)
Send Email: inquiry@market.us
Address: 420 Lexington Avenue, Suite 300 New York City, NY 10170, United States
Tel: +1 718 618 4351
Website: https://market.us
Posted in Testosterone
Comments Off on Global Testosterone Replacement Therapy Market Industry: A Latest Research Report to Share Market Insights and Dynamics – Healthcare News